Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada,…

Drug Manufacturers - General

US, Foster City [HQ]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Gilead Sciences, Inc.'s gradings, price targets and earnings estimates.

Earnings

See the historical earnings and what wall street analysts forecasted and
forecast for future earnings.

Reported

Past Estimate Consensus

Future Estimate Consensus

EPS Revenue EBITDA EBIT SGA

All monetary values are presented in USD ($). E stands for Estimate.
FY	EPS		Revenue [mil.]		Profit [mil.]		EBITDA [mil.]		EBIT [mil.]		Expenses · SGA [mil.]
		E		E		E		E		E		E
2014	2.0100	5.605	11,201	21,016	3,074	9,408	4,515	12,658	4,523	11,803	1,699	2,421
2015	7.9500	12.223	24,890	32,296	12,101	15,160	15,268	19,616	15,265	18,565	2,983	2,897
2016	12.3700	11.443	32,639	30,190	18,108	13,588	22,347	19,356	22,193	17,749	3,426	3,404
2017	10.0800	8.706	30,390	25,794	13,501	4,177	18,061	14,650	17,633	12,993	3,398	3,585
2018	3.5400	6.924	26,107	21,826	4,628	4,952	14,647	9,824	14,124	7,770	3,878	4,000
2019	4.2000	7.006	22,127	22,271	5,455	5,696	8,876	7,688	8,200	4,187	4,056	4,482
2020	4.2400	6.948	22,449	24,371	5,386	-826	6,155	3,240	4,287	2,949	4,381	5,218
2021	0.0708	8.205	24,689	26,669	89	5,087	8,509	9,870	9,927	8,387	5,151	5,287
2022	4.9600	7.103	27,305	26,527	6,225	3,230	9,456	7,213	10,095	5,827	5,246	5,458
2023	3.6600	6.755	27,281	27,098	4,592	1,054	10,393	7,934	10,974	6,410	5,673	6,004
2024	4.5400	3.798	27,116	27,730	5,665	4,777	11,701	9,858	9,368	7,784	6,060	5,697
2025	-	7.266	-	28,070	-	9,240	-	9,979	-	7,880	-	5,767
2026	-	7.742	-	29,037	-	2.F12X/td>	-	2.F121/td>	-	2.F121	-	2.F121
2027	-	8.279	-	30,239	-	1.F13X/td>	-	1.F131/td>	-	1.F131	-	1.F131
2028	-	8.844	-	31,365	-	0.F14X/td>	-	0.F141/td>	-	0.F141	-	0.F141

Institutional Sentiment

Wall Street · Earnings · Institutional Sentiment

The institutional sentiment measures the direction of new stock gradings
and price targets while comparing them Year-over-Year. We've limited the grading institutes to those we see as top-tier and update this data every month.

Morgan Stanley

1Y Ago:

Equal-Weight

Prev. Grade

Equal-Weight

Dec. 1, 2024

Equal-Weight

JP Morgan Chase

1Y Ago:

Overweight

Prev. Grade

Overweight

Dec. 1, 2024

Overweight

Citigroup

1Y Ago:

Underweight

Prev. Grade

n/a

Dec. 1, 2024

Underweight

Overall Consensus

Here we aggregate the price targets and gradings of all IBs/AMCs/Brokerage firms inside our database to draw a bigger picture.

Grading Consensus

Click to each, to see the grade

Price Target Consensus

+4.64% + $4.26 · MISS

Nov. 6, 2024

Price Then

$90.22

Price Target

$87.58

Price Now

$91.84